NCT03213405 - A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

rBCG-N-hRSV 1/100

5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.

BIOLOGICAL

rBCG-N-hRSV 1/10

5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.

BIOLOGICAL

rBCG-N-hRSV full dose

1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.

BIOLOGICAL

Conventional BCG full dose

2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.

Trial Locations (1)

Pontificia Universidad Católica de Chile, Santiago

All Listed Sponsors

collaborator

Comisión Nacional de Investigación Científica y Tecnológica

OTHER_GOV

collaborator

Millennium Institute on Immunology and Immunotherapy

OTHER

lead

Pontificia Universidad Catolica de Chile

OTHER